These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18219560)

  • 21. Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin.
    Chung JY; Cho JY; Lim HS; Kim JR; Yu KS; Lim KS; Shin SG; Jang IJ
    Drug Metab Dispos; 2011 Jan; 39(1):92-7. PubMed ID: 20876786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.
    Xie HJ; Yasar U; Lundgren S; Griskevicius L; Terelius Y; Hassan M; Rane A
    Pharmacogenomics J; 2003; 3(1):53-61. PubMed ID: 12629583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based.
    Richter T; Schwab M; Eichelbaum M; Zanger UM
    Biochem Pharmacol; 2005 Feb; 69(3):517-24. PubMed ID: 15652242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Roles of human CYP2A6 and 2B6 and rat CYP2C11 and 2B1 in the 10-hydroxylation of (-)-verbenone by liver microsomes.
    Miyazawa M; Sugie A; Shimada T
    Drug Metab Dispos; 2003 Aug; 31(8):1049-53. PubMed ID: 12867494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
    Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
    Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurement of in vitro cytochrome P450 2B6 activity.
    Walsky RL; Obach RS
    Curr Protoc Toxicol; 2009; Chapter 4():Unit4.27. PubMed ID: 23045012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
    Totah RA; Allen KE; Sheffels P; Whittington D; Kharasch ED
    J Pharmacol Exp Ther; 2007 Apr; 321(1):389-99. PubMed ID: 17259447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.
    Loboz KK; Gross AS; Williams KM; Liauw WS; Day RO; Blievernicht JK; Zanger UM; McLachlan AJ
    Clin Pharmacol Ther; 2006 Jul; 80(1):75-84. PubMed ID: 16815319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
    Kirchheiner J; Klein C; Meineke I; Sasse J; Zanger UM; Mürdter TE; Roots I; Brockmöller J
    Pharmacogenetics; 2003 Oct; 13(10):619-26. PubMed ID: 14515060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Artemisinin--a possible CYP2B6 probe substrate?
    Asimus S; Ashton M
    Biopharm Drug Dispos; 2009 Jul; 30(5):265-75. PubMed ID: 19562679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
    Robertson SM; Maldarelli F; Natarajan V; Formentini E; Alfaro RM; Penzak SR
    J Acquir Immune Defic Syndr; 2008 Dec; 49(5):513-9. PubMed ID: 18989234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition.
    Kharasch ED; Crafford A
    Clin Pharmacol Ther; 2019 Jan; 105(1):142-152. PubMed ID: 29756345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism.
    Crane AL; Klein K; Zanger UM; Olson JR
    Toxicology; 2012 Mar; 293(1-3):115-122. PubMed ID: 22281205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of marmoset CYP2B6: cDNA cloning, protein expression and enzymatic functions.
    Mayumi K; Hanioka N; Masuda K; Koeda A; Naito S; Miyata A; Narimatsu S
    Biochem Pharmacol; 2013 Apr; 85(8):1182-94. PubMed ID: 23395694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.
    Sridar C; Kenaan C; Hollenberg PF
    Drug Metab Dispos; 2012 Dec; 40(12):2256-66. PubMed ID: 22936314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
    Desta Z; Saussele T; Ward B; Blievernicht J; Li L; Klein K; Flockhart DA; Zanger UM
    Pharmacogenomics; 2007 Jun; 8(6):547-58. PubMed ID: 17559344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6.
    Gadel S; Crafford A; Regina K; Kharasch ED
    Drug Metab Dispos; 2013 Apr; 41(4):709-13. PubMed ID: 23298862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
    Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
    Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism of (-)-fenchone by CYP2A6 and CYP2B6 in human liver microsomes.
    Miyazawa M; Gyoubu K
    Xenobiotica; 2007 Feb; 37(2):194-204. PubMed ID: 17484521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions.
    Yamanaka H; Nakajima M; Fukami T; Sakai H; Nakamura A; Katoh M; Takamiya M; Aoki Y; Yokoi T
    Drug Metab Dispos; 2005 Dec; 33(12):1811-8. PubMed ID: 16135656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.